4D Molecular Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2013-01-01
- Employees
- 147
- Market Cap
- $807M
- Introduction
4DMT operates as a clinical-stage genetic medicines company focused on inventing and developing genetic medicines to treat large market diseases in ophthalmology, pulmonology and cardiology. It develops genetic medicines using its proprietary invention platform, Therapeutic Vector Evolution. It combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences. Its product design, development and manufacturing engine create a valuable and diverse product pipeline. The company is currently advancing five clinical-stage and two preclinical product candidates, each tailored to address rare and large market diseases. 4DMT was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.
4DMT Announces Positive Interim Data from 4D-150 SPECTRA Clinical Trial in DME and Alignment with FDA on Registrational Path
4D-150 shows promising safety and efficacy in DME patients, with significant visual acuity improvement and reduced injection burden. FDA supports a single Phase 3 trial for BLA submission, highlighting 4D-150's potential as a transformative therapy for VEGF-driven retinal diseases.
4DMT Announces Positive Interim Data from 4D-150
4DMT's 4D-150 shows promising results in DME treatment, with no intraocular inflammation and significant clinical activity. FDA agrees on a single Phase 3 trial for BLA submission. 3E10 vg/eye dose demonstrates +8.4 letters BCVA gain, -194 µm CST reduction, and 86% injection burden reduction compared to aflibercept 2mg Q8W.
4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME
4D Molecular Therapeutics focuses on advancing 4D-150 for wet AMD and DME, and 4D-710 for cystic fibrosis, with Phase 3 trials for 4D-150 set to begin in 2025. The company has extended its cash runway to 2028, supported by $506M in assets as of December 31, 2024, aiming to fund operations and clinical trials.
4DMT Announces Positive Interim Data from 4D-150 Showing Promising Safety and Efficacy in DME Patients
4D-150 shows promising safety and efficacy in DME patients, with significant visual acuity improvement and reduced injection burden. FDA supports a single Phase 3 trial for BLA submission, highlighting 4D-150's potential as a transformative therapy for DME and wet AMD.
Top 10 Fabry disease news stories of 2024
In 2024, Fabry Disease News highlighted key updates: gene therapy trials for Fabry disease showed promise, including AMT-191 and 4D-310 targeting heart and liver. Elfabrio slowed kidney decline. Studies found elevated inflammatory markers in patients and suggested small nerve fiber damage as a diagnostic aid. An algorithm using insurance data aims to speed up diagnosis. Chronic cough and pain were identified as potential Fabry symptoms.
4D Molecular Therapeutics, Inc. (NasdaqGS:FDMT) dropped from S&P Biotechnology Select
4D Molecular Therapeutics, Inc. (NasdaqGS:FDMT) dropped from S&P Biotechnology Select Industry Index.
4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies
4DMT's R100 vector shows superior retinal cell transduction over AAV2, with 4D-150 demonstrating potential in treating wet AMD and DME by suppressing VEGF-driven neovascularization. Clinical trials are ongoing, aiming for a Phase 3 start in 2025.
Fabry Disease Clinical Trials 2024: EMA, PDMA, FDA Approvals
DelveInsight's 'Fabry Disease Pipeline Insight, 2024' report details 18+ companies developing 18+ therapies, including Venglustat, Pegunigalsidase alfa, and 4D 310, with insights on mechanism of action, route of administration, and clinical trials. Key companies include Idorsia Pharmaceuticals, Protalix, Sanofi Genzyme, and Sangamo Therapeutics. The report covers pre-clinical to marketed phases, focusing on commercial and clinical assessments.
Global Organoids Market to Surge Significantly at a CAGR of ~14% by 2030
Global Organoids Market to grow at a CAGR of ~14% by 2030, driven by personalized medicine, organoid use in drug discovery, and cancer research. North America leads the market, with key players including Thermofisher Scientific Inc., StemCell Technologies Inc., and others. Organoids mimic human organs, aiding in disease modeling and drug testing, but face challenges like high costs and limited vascularization.
Non-Cystic Fibrosis Bronchiectasis Pipeline Insight: Over
Non-cystic fibrosis bronchiectasis market driven by rising prevalence, early diagnosis, and drug development. Over 15 companies, including Zambon SpA, Insmed, and AstraZeneca, are developing 15+ pipeline therapies. Key drugs in trials include Colistimethate sodium, Benralizumab, and Brensocatib.
© Copyright 2025. All Rights Reserved by MedPath